**Name of journal: World Journal of Meta-Analysis**

**ESPS Manuscript NO: 15875**

**Columns: EDITORIAL**

**Unsaturation index and type 2 diabetes: unknown, unloved**

Weijers RNM. Unsaturation index and type 2 diabetes

Rob NM Weijers

**Rob NM Weijers,** Teaching Hospital, Onze Lieve Vrouwe Gasthuis, 1090 HA, Amsterdam, The Netherlands

**Author contributions:** Weijers RNM solely contributed to this paper.

**Conflict-of-interest:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Rob NM Weijers, PhD,** Member of Teaching Hospital, Onze Lieve Vrouwe Gasthuis, Oosterparkstraat 9, PO Box 95500, 1090 HA, Amsterdam, The Netherlands. robw01@xs4all.nl

**Telephone:** +31-30-6362637

**Received:** December 14, 2014

**Peer-review started:** December 17, 2014

**First decision:** January 20, 2015

**Revised:** January 28, 2015

**Accepted:** April 1, 2015

**Article in press:**

**Published online:**

**Abstract**

A useful parameter for interpreting analyses of membrane fatty-acid composition is the unsaturation index (UI), a measure of unsaturation that is calculated as the mean number of *cis* double bonds per fatty-acid residue multiplied by 100. The UI is a fundamental parameter that contains information about many membrane biophysical properties and behavior. UI is a crucial index for type 2 diabetes (T2D) and other disorders, yet it is not properly considered in the scientific community. The goal of the present editorial is to familiarize the scientific T2D community with the UI. The idea of early systemic cell-membrane disease necessitates new thinking and suggests that UI should feature prominently on the research agenda.

**Key words:** Type 2 diabetes; Cell membrane; Unsaturation index; Phospholipid; Fatty acid

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** A useful parameter for interpreting analyses of membrane fatty-acid composition is the unsaturation index (UI), a mesure of unsaturationthat is calculated as the mean number of cis double bonds per fatty-acid residue multiplied by 100.The UI is a fundamental parameter that contains information about many membrane biophysical properties and behaviour. UI is a crucial index for type 2 diabetes (T2D) and other disorders, yet it is not properly considered in the scientific community. The goal of the present editorial is to familiarize the scientific T2D community with the UI.

Weijers RNM. Unsaturation index and type 2 diabetes: unknown, unloved. *World J Meta-Anal* 2015; In press

A useful parameter for interpreting analyses of membrane fatty-acid composition is the unsaturation index (UI), a measure of unsaturation that is calculated as the mean number of *cis* double bonds per fatty-acid residue multiplied by 100[1]. This parameter characterizes a phospholipid bilayer and describes the fluidity, or flexibility, of a biological membrane. As the UI increases, so does the distance between plasma-membrane fatty-acyl chains, decreasing their mutual attraction energy and thus increasing membrane flexibility, which promotes an increase in the number of all functional Class I glucose transporters per membrane surface area[2]. At the most basic level, the basal metabolic rate of a cell is directly linked to its cell membrane acyl composition, and thus to its UI[3]. To date, this relationship has not received due attention in the treatment for type 2 diabetes (T2D).

The UI is a fundamental parameter that contains information about many membrane biophysical properties and behavior. Arachidonic acid and docosahexaenoic acid are key fatty acids; a minimal increase in the percentage of arachidonic acid in phospholipid tails improves membrane flexibility due to its four double bonds. A similar effect is seen for docosahexaenoic acid, with its six unsaturated bonds. UI is a crucial index for T2D and other disorders, yet it is not properly considered in the scientific community[4]. The goal of the present editorial is to familiarize the scientific T2D community with the UI.

In the September issue of *PLoS ONE*, Koehrer *et al*[5] reported the erythrocyte phospholipid and polyunsaturated fatty-acid composition in diabetic retinopathy. Several points in this article require additional clarification. Given that the study consisted nearly exclusively T2D patients, the reported observations are likely to be restricted to this type of diabetes. In contrast to one previous publication, Koehrer *et al*[5] presented measurements of total phospholipids from red blood cells, with fatty-acid composition specified for a total of 26 fatty acids. Based on the presented data, we calculated the UIs of membrane phospholipids from control subjects, T2D patients with and without retinopathy, and patients with gestational diabetes mellitus[6]. For example, Table 1 describes the calculation of the UIs for controls and T2D patients without retinopathy included in the study of Koehrer *et al*[5].

The UIs based on the erythrocyte membrane fatty-acid compositions reported in these studies[5,6] yielded novel information (Table 2). First, although phosphatidylcholine and phosphatidylethanolamine comprise about 60% of the total phospholipid in the bilayer membrane of human erythrocytes, the red cell phosphatidylcholine and phosphatidylethanolamine UI of subjects with normal glucose tolerance in the gestational diabetes mellitus study[6] are in line with the total phospholipid UI of the reference population in the diabetic retinopathy study[5] (162.8 and 155.4, respectively; Δ = 4.5%). Second, the decrease in the UI of phosphatidylcholine and phosphatidylethanolamine for gestational diabetes mellitus patients relative to controls was substantially higher than the total phospholipid UI decrease for T2D individuals without diabetic retinopathy compared with controls (16.3% and 13.5%, respectively; Δ = 17.2%), due to two underlying phenomena, *i.e.,* a temporary gestational and a chronic prediabetic increase in plasma FFA[7]. Third, the total phospholipid UI was substantially lower in T2D individuals than in healthy controls (134.3 and 155.4, respectively; Δ = 13.5%). Finally, the mean total phospholipid UI was substantially lower in T2D individuals with mild, moderate, and severe diabetic retinopathy than in T2D individuals without diabetic retinopathy (123.4 and 134.3, respectively; Δ = 8.1%). These experimental outcomes indicate that membrane flexibility plays an important role in microvascular complications of T2D. Further, these data support our working hypothesis: a gradual elevation of the plasma levels of saturated and monounsaturated free fatty acids causes a decrease in the number of polyunsaturated fatty-acyl chains in membrane phospholipids[2], a classical principle of membrane biogenesis[3,8]. In this context, it is noteworthy that our working hypothesis predicts that the transition from a healthy condition to a state with T2D will be matched by a decrease in UI, as will the transition from T2D without diabetic retinopathy to T2D with retinopathy[2].

In a study of the relationship between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids, Borkman *et al*[9] concluded that reduced levels of unsaturated fatty acids in the membrane may be due to a net reduction in the action of insulin, as a consequence of either insulin resistance or insulin deficiency or, alternatively, as a consequence of hyperinsulinaemia. This interpretation seems unlikely for the following reasons: first, gestational diabetes mellitus is a marker of a prediabetic phase characterized by time-dependent increase in insulin levels[10,11], where the T2D phase is marked by a time-dependent decrease in insulin levels[11]. Second, we demonstrated that patients in both phases were associated with lower UIs than were healthy controls, which suggests that insulin levels do not have an important causative role in lowering the UI. We hypothesize that a gradual increase in plasma free fatty-acid concentration during the prediabetic phase and after overt T2D[12,13] decreases the UI[7].

A well-known characteristic of the euglycaemic hyperinsulinaemic clamp is its wide inter-subject variability in insulin sensitivity. In a study of metabolic effects of lacidipine: a placebo-controlled study using the euglycaemic hyperinsulinaemic clamp, Morris *et al*[14] reported that even amongst non-diabetic subjects who were homogeneous for age, sex and body weight there was a wide inter-subject variability in insulin sensitivity, *i.e*., 5.6–16.2 mg/kg·per minute where the intra-subject variability in insulin sensitivity on the two placebo study days was 9%. Since physical activity and caloric intake are individual entities, which significantly affect a persons’ free fatty acid concentration, we suggest that the wide inter-subject variability may be attributable to the inter-subject variability in free fatty acid concentration, and thus in the individual UI[13].

Despite extensive guidelines for managing T2D, in the United States during the years 2005-2008, 28.5% of adults with diabetes aged 40 years or older had diabetic retinopathy and 4.4% had advanced diabetic retinopathy[15]. These incidences are probably due to a longstanding period of decreased UI, increasing the stiffness of both the erythrocyte and plasma membranes and, as a consequence, decreasing microcirculatory flow, ultimately leading to chronic tissue hypoxia, insufficient tissue nutrition, and diabetes-specific microvascular pathology[2]. Thus, the idea of early systemic cell-membrane disease necessitates new thinking and suggests that UI should feature prominently on the research agenda.

**REFERENCES**

1 **Baur LA**, O'Connor J, Pan DA, Storlien LH. Relationships between maternal risk of insulin resistance and the child's muscle membrane fatty acid composition. *Diabetes* 1999; **48**: 112-116 [PMID: 9892230 DOI: 10.2337/diabetes.48.1.112]

2 **Weijers RN**. Lipid composition of cell membranes and its relevance in type 2 diabetes mellitus. *Curr Diabetes Rev* 2012; **8**: 390-400 [PMID: 22698081 DOI: 10.2174/157339912802083531]

3 **Hulbert AJ**. Life, death and membrane bilayers. *J Exp Biol* 2003; **206**: 2303-2311 [PMID: 12796449 DOI: 10.1242/jeb.00399]

4 **Chatgilialogou A**. U.I. arm in arm with Diabetes. Remembrane Blog, 2014 May 17. Available from: URL: http: //www.remembrane.com/en/n//u-i-arm-in-arm-with-diabetes/

5 **Koehrer P**, Saab S, Berdeaux O, Isaïco R, Grégoire S, Cabaret S, Bron AM, Creuzot-Garcher CP, Bretillon L, Acar N. Erythrocyte phospholipid and polyunsaturated fatty acid composition in diabetic retinopathy. *PLoS One* 2014; **9**: e106912 [PMID: 25188352 DOI: 10.1371/journal.pone.0106912]

6 **Min Y**, Ghebremeskel K, Lowy C, Thomas B, Crawford MA. Adverse effect of obesity on red cell membrane arachidonic and docosahexaenoic acids in gestational diabetes. *Diabetologia* 2004; **47**: 75-81 [PMID: 14634727 DOI: 10.1007/s00125-003-1275-5]

7 **Weijers RNM**. Membrane flexibility and cellular energy management in type 2 diabetes, gestational diabetes, and obesity. *EMJ Diabet* 2014; **2**: 65-72 [DOI: 10.13140/2.1.1027.6803]

8 **Gramling C**. Geochemistry. Low oxygen stifled animals' emergence, study says. *Science* 2014; **346**: 537 [PMID: 25359946 DOI: 10.1126/science.346.6209.537]

9 **Borkman M**, Storlien LH, Pan DA, Jenkins AB, Chisholm DJ, Campbell LV. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. *N Engl J Med* 1993; **328**: 238-244 [PMID: 8418404 DOI: 10.1056/NEJM199301283280404]

10 **Weijers RN**, Bekedam DJ, Smulders YM. Determinants of mild gestational hyperglycemia and gestational diabetes mellitus in a large dutch multiethnic cohort. *Diabetes Care* 2002; **25**: 72-77 [PMID: 11772904 DOI: 10.2337/diacare.25.1.72]

11 **Yki-Järvinen H**. Pathogenesis of non-insulin-dependent diabetes mellitus. *Lancet* 1994; **343**: 91-95 [PMID: 7903784 DOI: 10.1016/S0140-6736(94)90821-4]

12 **Laws A**, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. *Arterioscler Thromb Vasc Biol* 1997; **17**: 64-71 [PMID: 9012639 DOI: 10.1161/01.ATV.17.1.64]

13 **Reaven GM**, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. *Diabetes* 1988; **37**: 1020-1024 [PMID: 3292322 DOI: 10.2337/diab.37.8.1020]

14 **Morris AD**, Donnelly R, Connell JM, Reid JL. Metabolic effects of lacidipine: a placebo-controlled study using the euglycaemic hyperinsulinaemic clamp. *Br J Clin Pharmacol* 1993; **35**: 40-45 [PMID: 8448066]

15 **Centers for disease control and prevention**. National diabetes statistics report; estimates of diabetes and its burden in the United States. Available from: URL: http: //www.cdc.gov/diabetes/pubs/estimates14.htm

**P-Reviewer:** Biondi-Zoccai G, Brigo F, Loffredo l **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Unsaturation index of erythrocyte membrane fatty-acid composition**

**of controls and type 2 diabetes patients without diabetic retinopathy**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Fatty acids** | **Controls (*n* = 18)** | |  | **T2D patients without**  **diabetic retinopathy**  **(*n* = 14)** | |
|  | **% of total fatty acids1** | |  | **% of total fatty acids1** | |
|  |  | **× number of double bonds** |  |  | **× number of double bonds** |
| C14:0 | 0.43 | - |  | 0.48 | - |
| C15:0 | 0.17 | - |  | 0.22 | - |
| C16:0 | 22.41 | - |  | 23.75 | - |
| C17:0 | 0.38 | - |  | 0.44 | - |
| C18:0 | 17.22 | - |  | 17.72 | - |
| C20:0 | 0.15 | - |  | 0.18 | - |
| C22:0 | 0.33 | - |  | 0.42 | - |
| C24:0 | 0.74 | - |  | 0.78 | - |
| C16:1 | 0.73 | 0.73 |  | 1.03 | 1.03 |
| C18:1 (trans) | 0.22 | - |  | 0.20 | - |
| C18:1 | 17.16 | 17.16 |  | 19.15 | 19.15 |
| C20:1 n-9 | 0.21 | 0.21 |  | 0.26 | 0.26 |
| C20:3 n-9 | 0.19 | 0.57 |  | 0.20 | 0.60 |
| C22:1 n-9 | 0.06 | 0.06 |  | 0.09 | 0.09 |
| C24:1 n-9 | 0.69 | 0.69 |  | 1.15 | 1.15 |
| C18:2 n-6 | 12.87 | 25.74 |  | 10.58 | 21.16 |
| C18:3 n-6 | 0.09 | 0.27 |  | 0.12 | 0.36 |
| C20:2 n-6 | 0.20 | 0.40 |  | 0.23 | 0.46 |
| C20:3 n-6 | 1.30 | 3.90 |  | 1.50 | 4.50 |
| C20:4 n-6 | 13.04 | 52.16 |  | 11.33 | 45.32 |
| C22:4 n-6 | 2.00 | 8.00 |  | 2.01 | ` 8.04 |
| C22:5 n-6 | 0.35 | 1.75 |  | 0.30 | 1.50 |
| C18:3 n-3 | 0.22 | 0.66 |  | 0.21 | 0.63 |
| C20:5 n-3 | 0.97 | 4.85 |  | 1.03 | 5.15 |
| C22:5 n-3 | 2.23 | 11.15 |  | 1.56 | 7.80 |
| C22:6 n-3 | 4.51 | 27.06 |  | 2.85 | 17.10 |
| Unsaturation index2 |  | 155.36 |  |  | 134.30 |

1Data published by Koehrer *et al*[5]; 2The unsaturation index was calculated

as the mean number of double bonds per fatty acid residue multiplied by 100.

**Table 2 Calculated unsaturation indices based on erythrocyte fatty acid compositions reported by several studies**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Disease** | | **Participants (*n*)** | | **Erythrocyte**  **membrane** | **Unsaturation index1** | | **Decrease (%)** | **Ref.** | |
|  | **Controls** | **Disease** |  | **Controls** | **Diabetic subjects** |  | |  |
| T2D/T1D | | 18 | 13/1 | Total phospholipid | 155.4 | 134.3 | 13.5 | [5] | |
| T2D/T1D + mild DR | | 18 | 11/1 | Total phospholipid | 155.4 | 125.9 | 19.0 | [5] | |
| T2D/T1D + moderate DR | | 18 | 11/1 | Total phospholipid | 155.4 | 119.5 | 23.1 | [5] | |
| T2D/T1D + severe DR | | 18 | 19/3 | Total phospholipid | 155.4 | 124.7 | 19.7 | [5] | |
| T2D/T1D + proliferative DR | | 18 | 17/7 | Total phospholipid | 155.4 | 136.9 | 11.9 | [5] | |
| Gestational Diabetes | | 61 | 53 | PC + PE | 162.8 | 137.1 | 16.3 | [6] | |

**1**The unsaturation index was calculated as the mean number of double bonds per fatty acid residue multiplied by 100[4]. DR: Diabetic retinopathy; RBC: Red blood cell; PC: Phosphatidylcholine; PE: Phosphatidylethanolamine.